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Diagnosis and management of anti-Coª alloimmunisation during pregnancy is a rare 27 
and challenging condition. Only five cases have been described up to now, four in the 28 
1970s and one in 2008, but diagnosis and management has changed in the meantime 29 
(Smith, Stratton et al. 1970, Simpson 1973, McIntyre, Finigan et al. 1976, Fuhrmann, 30 
Kloppenburg et al. 1979, Michalewska, Wielgos et al. 2008). We here present such a 31 
case, its management and favourable outcome. 32 
Alloimmunisation of a Coª negative pregnant woman, carrying a Coª positive fetus, 33 
may cause haemolytic disease in the fetus and newborn (HDFN) (Smith, Stratton et al. 34 
1970, McIntyre, Finigan et al. 1976, Michalewska, Wielgos et al. 2008). Today, 35 
monitoring is performed by laboratory testing of antibody titer, although it is unknown 36 
whether antibody titration is helpful (de Haas, Thurik et al. 2015). Of greater importance 37 
are doppler flow measurements of the peak systolic velocity of the middle cerebral 38 
artery (MCA-PSV) (Zimmerman, Carpenter et al. 2002, Michalewska, Wielgos et al. 39 
2008, Moise and Argoti 2012, de Haas, Thurik et al. 2015). In cases of fetal anaemia, 40 
intrauterine blood  transfusion (IUT) by cordocentesis is established, challenged by the 41 
allocation of compatible blood (de Haas, Thurik et al. 2015).  42 
A 32-year-old woman (blood group 0 RhD-, RhC-, Rhc+, RhE-, Rhe+, K-, Coª-) was 43 
admitted to our hospital at 20+3 gestational weeks (gw) with an alloimmunisation 44 
against blood group antigen Coª with increasing antibody titer. Antibody identification 45 
was performed by indirect antiglobulin testing (IAT) and enzyme (papain) testing using 46 
an in-house panel and Coombs and neutral cards (IAT/ID and papain/ID) (BioRad, 47 
Cressier, Switzerland) (Table 1a). Titration was performed in IAT/ID using a Coa 48 
heterozygous test cell. A Coa antigen determination of the fetus` father, using IAT/ID 49 
and non-commercial anti-Coa and anti-Cob sera, showed that he was Coª homozygous. 50 
Monitoring of the fetus was performed every one to two weeks by MCA-PSV 51 
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measurements (Table 1b). Between 28 and 32 gw the MCA-PSV gradually increased 52 
with values above the 95th percentile and a Monocyte Monolayer Assay (MMA) showed 53 
a value of 29% (Nance, Nelson et al. 1989), so that anaemia was suspected and fetal 54 
transfusion planned. We used Coª-, RhD-, RhC-, RhE-and Kell negative blood from a 55 
donor, as women between 0 and 50 years of age should be transfused with Rh/K 56 
phenotype compatible blood only, according to the Swiss recommendations. We did 57 
not use blood from the mother, as autologous blood donation during pregnancy is not 58 
a common, but rarely performed procedure in Switzerland, especially in order to avoid 59 
lowering the mother`s haemoglobin level. At 32+4 gw a cordocentesis was performed. 60 
An immediate intrauterine transfusion was initiated already before the fetal blood result 61 
was present, in order to avoid a possible second cordocentesis due to a dislocated 62 
needle.  Knowing the haemoglobin/haematocrit of the fetus and of the preserved blood 63 
for transfusion, one can calculate the amount of blood needed to reach an appropriate 64 
fetal haemoglobin/haematocrit, according to the reference values by Mari (Mari, Deter 65 
et al. 2000). As the intraoperative blood results showed a haemoglobin and 66 
haematocrit of 123 g L-1 and 35.5 %, respectively, transfusion was stopped. So far, 40 67 
ml of RhD-, RhC-, RhE-, Kell- and Coª negative, irradiated and washed red blood cells, 68 
depleted for plasma and leucocytes, with a haematocrit of 81.3 % were transfused, 69 
leading to a posttransfusion haemoglobin level and haematocrit of 168 g L-1 and 48.7 70 
%, respectively. MCA-PSV decreased to normal values within minutes and remained 71 
stable (Table 1b). Delivery was performed at 37+2 gw by elective cesarean as part of 72 
our standard protocol for alloimmunised pregnancies. Blood testing of the newborn 73 
confirmed blood group A RhD negative with antibodies against Coª, detected by direct 74 
antiglobulin testing (DAT) (agglutination ++, eluate testing positive). Fetal umbilical 75 
cord haemoglobin and haematocrit levels were 156 g L-1 and 47%, respectively (Table 76 
1a). Due to fetal hyperbilirubinaemia on the fifth day postpartum, the neonate was 77 
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treated with phototherapy for three days (Table 1a). This was the reason, why mother 78 
and child were discharged from hospital not before eight days postpartum, both without 79 
complications. 80 
Given the limited data on the relevance of antibody titer, close monitoring of the mother 81 
and fetus was justified. Repeated antibody screening was performed for early detection 82 
of a titer increase. Although a significant increase in antibody titer was documented, 83 
this did not reflect fetal anaemia. Unfortunately, a clear cutoff for anti- Coª antibody 84 
titers, leading to fetal anaemia, is lacking (de Haas, Thurik et al. 2015). In our and other 85 
cases of severe fetal anaemia, the antibody titer was measured at a level of 1:128 in 86 
IAT and in a case of mild HDFN the titer was only 1:32 (Simpson 1973, McIntyre, 87 
Finigan et al. 1976, Michalewska, Wielgos et al. 2008). Here, however, it is important 88 
to consider the different methods of antibody titer determination used in the 1970s and 89 
nowadays. Additionally, a MMA can be performed to evaluate the clinical significance 90 
of the antibody. Monocyte reactivity greater than 20% was initially reported to correlate 91 
with needs for transfusion (Nance, Arndt et al. 1987). Subsequent studies from the 92 
same author, however, indicated that the assay may not always predict the outcome 93 
of the infant, as seen in our case, and should not be used to evaluate HDFN. Before 94 
diagnosing fetal anaemia by MCA-PSV, bilirubin extinction in amniotic fluid from 95 
amniocentesis was performed (Moise and Argoti 2012, de Haas, Thurik et al. 2015). 96 
This method was used in the four cases in the 1970s, but required repeated 97 
amniocentesis with the risks of an invasive procedure (Simpson 1973, McIntyre, 98 
Finigan et al. 1976, Fuhrmann, Kloppenburg et al. 1979). Measurement of the MCA-99 
PSV is the gold standard nowadays and was performed in our and Michalewska`s case 100 
(Mari, Adrignolo et al. 1995, Michalewska, Wielgos et al. 2008). Compared to that case, 101 
where MoM-values for the MCA-PSV cutoff were used, we used the reference values 102 
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published by Kurmanavicius (Mari, Adrignolo et al. 1995, Kurmanavicius, Streicher et 103 
al. 2001). However, in our case MCA-PSV values indicative for fetal anaemia also 104 
exceeded the MoM-values by Mari. No neonatal exchange or top-up transfusion was 105 
required in our case and in the ones of McIntyre and Smith, but in the other cases 106 
(Table 2). Although MCA-PSV values were indicative for fetal anaemia in our case, 107 
blood values were almost normal for the age of gestation.  108 
The neonatal hyperbilirubinaemia, treated with phototherapy for three days, was 109 
probably not due to alloimmunisation against Coª, but in the context of intensified 110 
postpartum haemolysis. 111 
A great challenge in anti-Coª alloimmunised patients is the allocation of compatible 112 
blood for transfusion.  In Switzerland, this can be achieved by finding a donor through 113 
the “DGTI Rare Donor Register” (http://www.iblutspende.ch/rare-donors.html), by 114 
autologous donation of maternal blood or by transfusion of washed maternal 115 
erythrocytes (not a common procedure, limited to rare cases with missing compatible 116 
blood donors). In this case, the possible selection was even smaller due to the 0 RhD 117 
negative blood group of the patient (only 6% of blood donors). Only seven donors were 118 
compatible for the constellation RhD-, RhC, RhE-, K- and Coª negative in Switzerland 119 
and only three of them available at that time. Furthermore, preparation time of two to 120 
three days had to be taken into consideration. Unfortunately, non-invasive treatment 121 
options are not available up to date.  122 
Anti-Coª alloimmunisation during pregnancy is a challenging situation.  Both national 123 
and international blood donor registries are extremely helpful to identify compatible 124 
blood donors. Despite increased antibody concentrations, MCA-PSV and MMA, this 125 
case did not develop fetal or neonatal anaemia and did not require exchange 126 
transfusion after birth. Serologic methods can help to initiate fetal monitoring and 127 
 6 
 
doppler MCA-PSV measurements might be helpful to avoid serial amniocentesis or 128 
fetal blood samplings, but can also be misleading in some cases.   129 
 130 
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Table 1:  154 
a) Haematological course of mother and fetus/neonate 155 
gestational  
weeks 
anti-
Coª 
titer 
maternal 
haemoglobin 
(g/100mL) 
maternal 
haematocrit 
(%) 
fetal/neonatal 
haemoglobin 
(g/100mL) 
fetal/neonatal 
haematocrit 
(%) 
Neonatal 
blood 
bilirubin 
(mcmol/L) 
neonatal 
transcutaneous 
bilirubin 
(mcmol/L) 
6+3  2             
10+2 8 121 36         
13+2  16             
16+3 32             
20+3 128 129 37.6         
30+3 16             
32+4 (before transfusion)   127 37.5 123 35.5     
32+4 (after transfusion)       168 48.7     
37+1   122 35.3         
37+2 (cesarean)       156 47 39 59 
1st day postpartum   117 35.8   56 105 109 
2nd day postpartum         56 200 179 
3rd day postpartum             225 
4th day postpartum         55 276 241 
5th day postpartum         56 300   
6th day postpartum         55 281   
7th day postpartum         61 299   
8th day postpartum         57 258   
 156 
b) MCA-PSV values in the course of pregnancy 157 
gestational 
weeks 
MCA -PSV 
(cm/s) 
20+3 27 
22+3  32 
24+3 39 
26+3 45 
28+3 54* 
29+3  60* 
29+6  60* 
30+3 65* 
30+5 61* 
31+3 62* 
31+6 74* 
32+2 72* 
32+4 (before transfusion) 72* 
32+4 (after transfusion) 43 
32+5 54 
33+5 63 
34+6 65 
36+4 72 
*Value above the 95th percentile of reference limits 158 
 159 
 160 
Table 2: Course and outcome of the six cases 161 
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Case 
Anit-
Coª 
titer 
Amnicentesis 
(n) 
Cord 
blood 
sampling 
(n) 
Fetal 
anaemia 
Intrauterine 
transfusion 
(n) 
Neonatal 
anaemia 
neonatal 
transfusion 
(n) 
Smith 1970  0 0 none 0 none 0 
Simpson 1973 128 2 0 severe 0 severe 2 
McIntyre 1976 32 1 0 none 0 none 0 
Fuhrmann 1979  2 0 mild 0 severe* 2* 
Michalewska 2008 128 0 3 severe 1 severe 5 
Our case 128 0 1 mild 1 mild 0 
*due to bleeding out of a ruptured of vessel in presence of insertio velamentosa 162 
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